Finasteride in Hospitalized Adult Males with COVID-19: A Risk Factor for Severity or an Adjunct Treatment - A Randomized Controlled Clinical Trial

    April 2021 in “ Medical journal of the Islamic Republic of Iran ”
    Elham Zarehoseinzade, Abbas Allami, Mehrnoosh Ahmadi … Navid Mohammadi
    Studysummary This study found that a short course of finasteride improved oxygen saturation but had no significant impact on mortality rate or length of hospital stay in older male COVID-19 pneumonia patients.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mjiri.iums.ac.ir →
    Discuss this study in the Community →

    Research cited in this study 7

    1. Anti-Androgens May Protect Against Severe COVID-19 Outcomes: Results From a Prospective Cohort Study of 77 Hospitalized Men Journal of The European Academy of Dermatology and Venereology · 2021
    2. 5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia Journal of The European Academy of Dermatology and Venereology · 2020
    3. Androgen Sensitivity Gateway to COVID-19 Disease Severity Drug Development Research · 2020
    4. Effects of 5-Alpha Reductase Inhibitors on Lung Function: A Reason for Discontinuation During COVID-19 Pandemic? Dermatologic Therapy · 2020
    5. May Patients Receiving 5-Alpha-Reductase Inhibitors Be at Higher Risk of COVID-19 Complications? Medical hypotheses · 2020
    6. What Does Androgenetic Alopecia Have to Do with COVID-19? An Insight into a Potential New Therapy Dermatologic Therapy · 2020
    7. Adverse Effects and Safety of 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review PubMed · 2016